Holen Sie sich die Stockscreener-App
1.66
12.93%
0.19
Handel nachbörslich:
1.63
-0.03
-1.81%
Schlusskurs vom Vortag:
$1.47
Offen:
$1.46
24-Stunden-Volumen:
530.23K
Relative Volume:
0.45
Marktkapitalisierung:
$104.73M
Einnahmen:
$139.77M
Nettoeinkommen (Verlust:
$-97.62M
KGV:
-1.0506
EPS:
-1.58
Netto-Cashflow:
$-61.71M
1W Leistung:
+3.11%
1M Leistung:
+3.11%
6M Leistung:
-32.52%
1J Leistung:
-52.97%
1-Tages-Spanne:
$1.46
$1.67
1-Wochen-Bereich:
$1.43
$1.67
52-Wochen-Spanne:
$0.9897
$5.10
Macrogenics Inc Stock (MGNX) Company Profile
Firmenname
Macrogenics Inc
Sektor
Branche
Telefon
301-251-5172
Adresse
9704 MEDICAL CENTER DRIVE, Rockville, MD
Vergleichen Sie MGNX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
1.66 | 92.74M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-07 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-31 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-05-10 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | Herabstufung | Stifel | Buy → Hold |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-04-26 | Eingeleitet | B. Riley Securities | Buy |
| 2024-04-09 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-03-04 | Bestätigt | BTIG Research | Buy |
| 2024-02-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-11-22 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-11-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | Herabstufung | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-02-28 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-04 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Buy |
| 2021-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-12 | Hochstufung | Barclays | Underweight → Overweight |
| 2020-12-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-06-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-05-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Underweight |
| 2019-12-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-11-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | Fortgesetzt | Guggenheim | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Guggenheim | Neutral |
| 2019-02-07 | Hochstufung | Citigroup | Sell → Buy |
| 2019-02-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-02-06 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-12-10 | Herabstufung | Raymond James | Outperform → Underperform |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-05-31 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-03-31 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Macrogenics Inc Aktie (MGNX) Neueste Nachrichten
MacroGenics names Eric Risser as new CEO, succeeding Scott Koenig By Investing.com - Investing.com Nigeria
MacroGenics Appoints Eric Risser as New CEO - TipRanks
MacroGenics appoints Eric Risser as new CEO, succeeding Scott Koenig By Investing.com - Investing.com Australia
MacroGenics Appoints Eric Risser as President and Chief Executive Officer - GlobeNewswire
MacroGenics Taps Deal-Making Expert Eric Risser as CEO After 24-Year Leadership Run Ends - Stock Titan
How liquid is MacroGenics Inc. stockBreakout Stocks for Quick Return - mustnews.co.kr
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics, Inc. LawsuitMGNX - ACCESS Newswire
What makes MacroGenics Inc. stock price move sharplyFast-track wealth growth - Jammu Links News
What analysts say about MacroGenics Inc. stockUnmatched profit growth - Jammu Links News
How volatile is MacroGenics Inc. stock compared to the marketAccelerate your capital gains today - Jammu Links News
Does MacroGenics Inc. stock perform well during market downturnsInvest smarter with high-probability setups - Jammu Links News
What institutional investors are buying MacroGenics Inc. stockDynamic investment opportunities - Jammu Links News
What are the latest earnings results for MacroGenics Inc.Unbelievable profit margins - Jammu Links News
What are MacroGenics Inc. company’s key revenue driversHigh-yield investments - Jammu Links News
Is MacroGenics Inc. a growth stock or a value stockSuperior return velocity - Jammu Links News
How strong is MacroGenics Inc. company’s balance sheetEntry Signal Growth Plan For Every Investor - Jammu Links News
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics LawsuitMGNX - ACCESS Newswire
MacroGenics’ Prostate Cancer Study: A Potential Game-Changer? - TipRanks
Why MacroGenics Inc. stock attracts strong analyst attentionTriple Digit Return Stock Predictions Released - metal.it
MacroGenics’ Phase 2 Study: A Potential Game-Changer in Prostate Cancer Treatment? - TipRanks
RSI and MACD Indicate Shift in MacroGenics Inc. SentimentProven Entry Plan With Low Risk Shared - metal.it
Is MacroGenics Inc. Starting a New UptrendBuy Low Sell High Stock Watch Strategy in Focus - metal.it
MacroGenics’ Promising Study on Advanced Solid Tumors: Key Insights for Investors - TipRanks
Will MacroGenics Inc. see short term momentumWeekly Trend Watch with Market Signals - Newser
What the charts say about MacroGenics Inc. todayGrowth Summary Based on Market Positioning - Newser
Analyzing MacroGenics Inc. with multi timeframe chartsFree Trend Following Strategy With Stop Loss - Newser
How does MacroGenics Inc. generate profit in a changing economyAchieve breakthrough gains with expert advice - Jammu Links News
What catalysts could drive MacroGenics Inc. stock higher in 2025Invest confidently with real-time market updates - Jammu Links News
What is MacroGenics Inc. company’s growth strategyRealize consistent double-digit growth - Jammu Links News
Why is MacroGenics Inc. stock attracting strong analyst attentionAchieve rapid wealth accumulation with smart picks - Jammu Links News
When is MacroGenics Inc. stock expected to show significant growthUnstoppable trading performance - Jammu Links News
How MacroGenics Inc. stock performs during market volatilityProven Return Strategy Execution - metal.it
Moving Average Trends for MacroGenics Inc. Stock: What They IndicateElite Stock Shortlist - Newser
MacroGenics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayFree Access to Investment Community - Newser
Finanzdaten der Macrogenics Inc-Aktie (MGNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):